Health
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? – Motley Fool Australia
This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna(NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year,…
-
General21 hours agoOf saints and sinners | The Spectator Australia
-
General21 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General22 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News12 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones